Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 17:13:969565.
doi: 10.3389/fphar.2022.969565. eCollection 2022.

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option

Hong-Hong Zhang  1   2 , Xiao-Jing Du  1 , Mei-Ling Deng  1 , Lie Zheng  3 , Dun-Chen Yao  1 , Zhi-Qiang Wang  1 , Qun-Ying Yang  4 , Shao-Xiong Wu  1
Affiliations

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option

Hong-Hong Zhang et al. Front Pharmacol. .

Abstract

Purpose: The recurrent/progressive glioblastoma multiforme (GBM) carries a dismal prognosis and the definitive treatment strategy has not yet been established. This study aimed to assess the efficacy and safety of apatinib in recurrent/progressive GBM patients. Materials and methods: The clinical data of 19 recurrent/progressive GBM patients who received apatinib treatment from November 2015 to December 2019 at Sun Yat-sen University Cancer Center were collected retrospectively in this study. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (AEs) were reviewed and assessed. Results: The overall ORR was 52.6%, and the DCR was 73.7%. Median PFS and OS were 5.1 and 10.4 months, respectively. The 6-month PFS and OS rates were 38.9% and 68.4%, respectively. The 12-month PFS and OS rates were 16.7% and 36.8%, respectively. The treatment-related toxicities were generally well-tolerated. The most common grade 3/4 AEs were hand-foot syndrome (36.8%) and hypertension (21.1%). Conclusion: Our study showed that apatinib therapy provided a better salvaging option for recurrent/progressive GBM patients and the toxicity was manageable.

Keywords: VEGFR; apatinib; efficacy; recurrent/progressive glioblastoma multiforme; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Brain scan of a patient with left frontotemporal glioblastoma multiforme who had relapsed from surgery, standard chemoradiotherapy regimen, and ten cycles of adjuvant temozolomide, and then had progressed after bevacizumab treatment. Comparison of imaging findings between pre-treatment (A) and post-treatment at 4 months of apatinib monotherapy (B) by contrast-enhanced MRI and MRI-Flair. The patient achieved partial response after treatment and had a progression-free survival time of 5.3 months.
FIGURE 2
FIGURE 2
Swimmer plot of treatment responses.
FIGURE 3
FIGURE 3
Kaplan-Meier estimate for progression-free survival (A) and overall survival (B) for all patients.
FIGURE 4
FIGURE 4
Kaplan-Meier progression-free survival curves (A) and overall survival curves (B) for patients stratified by experiencing hypertension or not.
See this image and copyright information in PMC

References

    1. Ahir B. K., Engelhard H. H., Lakka S. S. (2020). Tumor development and angiogenesis in adult brain tumor: Glioblastoma. Mol. Neurobiol. 57 (5), 2461–2478. 10.1007/s12035-020-01892-8 - DOI - PMC - PubMed
    1. Audureau E., Chivet A., Ursu R., Corns R., Metellus P., Noel G., et al. (2018). Prognostic factors for survival in adult patients with recurrent glioblastoma: A decision-tree-based model. J. Neurooncol. 136 (3), 565–576. 10.1007/s11060-017-2685-4 - DOI - PubMed
    1. Azad N. S., Aragon-Ching J. B., Dahut W. L., Gutierrez M., Figg W. D., Jain L., et al. (2009). Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin. Cancer Res. 15 (4), 1411–1416. 10.1158/1078-0432.CCR-08-1141 - DOI - PMC - PubMed
    1. Ding X., Jujie S., Tingyong F., Baosheng L. (2018). A case report of targeted therapy with apatinib in a patient with recurrent high grade glioma. Medicine 97 (22), e10859. 10.1097/MD.0000000000010859 - DOI - PMC - PubMed
    1. Fischer A., Wu S., Ho A. L., Lacouture M. E. (2013). The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Investig. New Drugs 31 (3), 787–797. 10.1007/s10637-013-9927-x - DOI - PubMed

LinkOut - more resources